舒洛地特联合缬沙坦对早期糖尿病肾病疗效临床研究被引量：2

Effect of Combination of Sulodexide and Valsartan in Early Diabetic Nephropathy

下载PDF

导出

摘要目的:观察舒洛地特联合缬沙坦对早期糖尿病肾病的疗效。方法:将我院就诊的早期DN患者60例,随机分为对照组和治疗组,两组同时给予常规综合治疗。对照组给予缬沙坦80mg口服,每日1次,共7周;治疗组在此基础上加用舒洛地特600LSU肌注,每日1次,15天后改为250LSU口服,每日两次,总疗程7周。检测两组患者在治疗前后的FBG,尿白蛋白排泄率(UAER),胱抑素C(Cystatin C),血FIB,血浆纤溶酶原活化物抑制剂(PAI-1)。结果:两组治疗后UAER,Cystatin C,FBG,FIB,PAI-1均有降低,P<0.05,两组比较,治疗组治疗后UAER,Cystatin C,FBG,FIB,PAI-1比对照组降低,P<0.05。结论:舒洛地特联合缬沙坦可有效的降低尿蛋白,减轻肾脏损伤,效果明显。 Objective：To observe the effect of combination of suledexide and valsartan in early diabetic nephropathy. Methods：60 cases of DN were divided into two groups; one group was given valsartan, 80rag, qd, 7w, the other group was aslo given sulodexide 600 LSU im qd, 15d, then 250LSU, po,7w. To monitor the UAER, Cystatin C, FBG, FIB, PAI - 1 before and after treatment. Results： After treatment, the UAER,Cystatin C,FBG,FIB,PAI - 1 of both groups were lower,P 〈 0. 05, tThe treatment group compared with the control group significantly improved in UAER, Cystatin C, FBG, FIB, PAI- 1, P 〈 0. 05. Conclusion： Combination of suledcxidc and valsartan can improve rennal function in early diabetic nephropathy.

作者董晓辉王勤学王宝英徐岩

机构地区胶州市人民医院血液净化中心青岛大学医学院附属医院肾内科

出处《黑龙江医药》 CAS 2011年第6期949-950,共2页 Heilongjiang Medicine journal

关键词舒洛地特缬沙坦糖尿病肾病 suledexide valsartan diabetic nephropathy

分类号 R692.5 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献2

1张有才,刘章锁,张华,张明轩.缬沙坦对糖尿病大鼠肾脏的保护作用[J].中华肾脏病杂志,2000,16(5):330-331. 被引量：38
2舒冏,曾龙驿,王曼曼,林可意,傅静亦,张国超.舒洛地特对大鼠糖尿病肾脏的保护作用及其机制[J].中国医院药学杂志,2009,29(1):19-23. 被引量：15

二级参考文献10

1于德民,吴锐,尹潍,袁咏.实验性链脲佐菌素糖尿病动物模型的研究[J].中国糖尿病杂志,1995,3(2):105-109. 被引量：425
2高鑫,左静南.实验性糖尿病大鼠早期肾脏结构和功能的改变[J].中华肾脏病杂志,1989,5(2):71-75. 被引量：17
3何兰杰,刘萍.枸杞多糖对糖尿病大鼠肾脏氧化应激的影响[J].中国医院药学杂志,2006,26(12):1475-1478. 被引量：24
4Lee FT, Cao Z, LongDM, et al. Interactions between angiotensin II and NF-κB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy[J]. J Am Soc Nephrol,2004,15(8) :2139-2151.
5Solini A, Vercnani L, Ricci F, et al. Glycosaminoglycans delay the progression of nephropathy in NIDDM[J]. Diabetes Care , 1997 ,20 (5):819.
6Kim Y, Fischer SM. Transcriptional regulation of cyclooxygenase-2 in mouse skin carcinoma cells. Regulatory role of CCAAT/enhaneer-binding proteins in the differential expression of cyclooxygenase-2 in normal and neoplastic tissues[J]. J Biol Chem, 1998,273 : 27686-27694.
7Drel VR,Pacher P, Stevens MJ, et al. Aldose reductase inhibition counteracts nitrosative stress and Poly (ADP-ribose) Polymerase activation in diabetic rat kidney and high glucose-exposed human mesangial cells[J]. Free Radic Biol Med,2006,40 (8) : 1454-65.
8Chen L,Jia RH,Qiu CJ,et al. Hyperglycemia inhibita the uptake of dehydroascorhate in tubular epithelial cell[J]. Am J Nephrol,2005,25 : 459-465.
9Floege J, Eng E, Uoung BA,et al. Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferation. Glomerulonephritis [ J ]. Kindey International, 1993,43 : 269.
10Manduteanu I, Voinea M, Antohe F, et al. Effect of enoxaparin on high glucose-induced activatio of endothelial cells [J]. European Journal of Pharmacology, 2003,477(5) :269.